unknown
Stage
2
Investors
About
Enterprise Therapeutics develops novel therapies targeting ion channels for the treatment of respiratory diseases such as cystic fibrosis and chronic obstructive pulmonary disease (COPD).
Explore Enterprise Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.